Evidence map›Paper›PMID 26867670›Full record

ArticleLeukemia2016

Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.

S Soverini, C De Benedittis, C Papayannidis, K Machova Polakova, C Venturi, D Russo, P Bresciani, A Iurlo, M Mancini, A Vitale and 9 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Detection ofHaematologica · 2022
    Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

S SoveriniDepartment of Experimental, Diagnostic and Specialty Medicine, Hematology/Oncology 'L. e A. Seràgnoli', University of Bologna, Bologna, Italy.ORCID 0000-0002-4508-0353
C De BenedittisDepartment of Experimental, Diagnostic and Specialty Medicine, Hematology/Oncology 'L. e A. Seràgnoli', University of Bologna, Bologna, Italy.
C PapayannidisDepartment of Experimental, Diagnostic and Specialty Medicine, Hematology/Oncology 'L. e A. Seràgnoli', University of Bologna, Bologna, Italy.
K Machova PolakovaInstitute of Hematology and Blood Transfusion, Prague, Czech Republic.
C VenturiDepartment of Experimental, Diagnostic and Specialty Medicine, Hematology/Oncology 'L. e A. Seràgnoli', University of Bologna, Bologna, Italy.
D RussoChair of Hematology, Unit of Blood Diseases and Stem Cell Transplantation, University of Brescia, Brescia, Italy.
P BrescianiBone Marrow Transplant Unit, Department of Oncology and Hematology, University of Modena, Modena, Italy.
A IurloOnco-Hematology Division, IRCCS Ca' Granda-Maggiore Policlinico Hospital Foundation, Milan, Italy.
M ManciniDepartment of Experimental, Diagnostic and Specialty Medicine, Hematology/Oncology 'L. e A. Seràgnoli', University of Bologna, Bologna, Italy.
A VitaleHematology, Department of Cellular Biotechnologies and Hematology, La Sapienza University, Rome, Italy.
S ChiarettiHematology, Department of Cellular Biotechnologies and Hematology, La Sapienza University, Rome, Italy.
R FoàHematology, Department of Cellular Biotechnologies and Hematology, La Sapienza University, Rome, Italy.
E AbruzzeseHematology, S. Eugenio Hospital, Tor Vergata University, Rome, Italy.
F SoràHematology, Università Cattolica del Sacro Cuore, Rome, Italy.
A KohlmannPersonalised Healthcare and Biomarkers, AstraZeneca, Cambridge, UK.
T HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.
M BaccaraniDepartment of Experimental, Diagnostic and Specialty Medicine, Hematology/Oncology 'L. e A. Seràgnoli', University of Bologna, Bologna, Italy.
M CavoDepartment of Experimental, Diagnostic and Specialty Medicine, Hematology/Oncology 'L. e A. Seràgnoli', University of Bologna, Bologna, Italy.
G MartinelliDepartment of Experimental, Diagnostic and Specialty Medicine, Hematology/Oncology 'L. e A. Seràgnoli', University of Bologna, Bologna, Italy.

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
PAARK4Kids-Pharmacogenomics of Anticancer Agents Research in ChildrenU01GM092666 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2010 to 2014
$8.9M
Glucocorticoids in Lymphoblastic LeukemiaR01CA142665 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2010 to 2020
$4.6M
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAntineoplastic AgentsDNA Mutational AnalysisDrug Resistance, NeoplasmFemaleFusion Proteins, bcr-ablHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationNeoplasm Recurrence, LocalNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Kinase InhibitorsAntineoplastic AgentsBCR-ABL1 fusion protein, humanFusion Proteins, bcr-ablProtein Kinase Inhibitors

Identifiers

PMID26867670

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.